TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06683547

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Monoester (KET)
Description: Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight). The ketone brand name: delta G Oxford Ketone Ester.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavour matched placebo drink (CON)
Description: - Flavoured water (non-caloric bitter + citrus flavours)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: - 5 sets of 10 repetitions of leg press and 3 sets of 12 repetitions of leg extension/leg curl 'supersets' (1 set of each back to back with no rest in between sets) at 95% of their 10-RM. Between-set rest intervals for the leg exercises will be 60 seconds.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise
Description: - 5 sets of 10 repetitions of leg press and 3 sets of 12 repetitions of leg extension/leg curl 'supersets' (1 set of each back to back with no rest in between sets) at 95% of their 10-RM. Between-set rest intervals for the leg exercises will be 60 seconds.
Study: NCT06316557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS group
Description: iTBS on the contralesional cerebellum, twice a day for seven days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: shame stimulation on the contralesional cerebellum, twice a day for seven days
Study: NCT06205316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Receive ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Receive ADT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study
Study: NCT06695026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001 Dose 1
Description: RZ-001 Dose 1 and VGCV, Atezolizumab/Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001 Dose 2
Description: RZ-001 Dose 2 and VGCV, Atezolizumab/Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001 Dose 3
Description: RZ-001 Dose 3 and VGCV, Atezolizumab/Bevacizumab
Study: NCT06689930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDSA Cycles
Description: Conduct PDSA cycle and follow-up interviews and surveys for patients (5 per cycle, 10 total) and CBO staff (no less than 2)
Study: NCT06627244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Description: Tebentafusp will be administered intravenously to participants at or within 28 days of their first Y-90 TARE procedure. This 28-day period includes the 14- to 28-day Y-90 TARE Recovery Period. For administrative purposes, one cycle of tebentafusp treatment is 28 days in length. Tebentafusp will be administered on a dose escalation schedule for Cycle 1 starting at 20 mcg on Day 1, increasing to 30 mcg on Day 8, and a final dose of 68 mcg on Day 15, which will be administered once per week until unacceptable toxicity develops, disease progression, or withdrawal of consent, whichever occurs first.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
Description: Participants will undergo radiographic and 99mTC-labeled macroaggregated albumin (99mTc-MAA) assessment for suitability prior to Y-90 absorbed glass microsphere treatment per institutional procedures. Y-90 trans-arterial radioembolization (TARE) is a standard of care treatment for intrahepatic metastases of uveal melanoma as indicated in the National Comprehensive Cancer Network (NCCN) consensus guidelines (NCCN Guidelines®, 2023). Y-90 absorbed glass microspheres will be administered at least one time prior to initiating Tebentafusp treatment. After the Y90-TARE procedure, participants will have a 14- to 28-day Y-90 TARE Recovery Period.
Study: NCT06632379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10 mg
Description: Participants will be assigned to 10 mg Atorvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be assigned to identical appearing placebo
Study: NCT06688201

Intervention type: OTHER
Group type: OTHER
Intervention: Other neurosurgical techniques
Description: Those include open craniotomy, small skull window microsurgery, and endoscopic surgery. The attending clinician is required to consider which type of craniotomy or other procedure according to the expertise and availability at the hospital.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Soft Channel Brain Haemorrhage Evacuation
Description: This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
Study: NCT06717321

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: (Arm 1): PEG
Description: A 20-French pull type percutaneous endoscopic feeding tube placed into the stomach using endoscopic guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: (Arm 2): PEG-J
Description: 24-French pull type percutaneous endoscopic feeding tube placed into the stomach with a 12-French jejunal extension tube advanced through the PEG and positioned post-pyloric in the small bowel using endoscopic guidance
Study: NCT06707883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2731 injection
Description: TQC2731 injection is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC2731 Placebo
Description: TQC2731 Placebo without drug substance.
Study: NCT06727773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: memantine capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: memantine capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Exercise Intervention participants will concurrently engage in remotely delivered Get Real \& Heel, 3d/week. Intensity for aerobic and strength-training components will progress as tolerated under the direction of a trained exercise physiologist.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Intervention
Description: Exercise Intervention participants will concurrently engage in remotely delivered Get Real \& Heel, 3d/week. Intensity for aerobic and strength-training components will progress as tolerated under the direction of a trained exercise physiologist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Control
Description: Exercise control will have access to a library of pre-recorded Get Real \& Heel sessions.
Study: NCT06747507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir Pill
Description: Dose will be based on weight; brand names will be as supplied through the respective national programs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir+Ritonavir
Description: Dose will be based on weight
Study: NCT06757504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01 Tablets (12mg or 18mg)
Description: Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01 Tablets (12mg or 18mg)
Description: Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Simulant TTYP01 Tablets)
Description: Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Simulant TTYP01 Tablets)
Description: Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Simulant TTYP01 Tablets)
Description: Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
Study: NCT06760793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual static stretching exercises on plantar flexors
Description: A manual static stretching exercises was performed on the plantar flexors in both knee extension and flexion. The stretch was applied while the participant was in a prone position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep friction massage on plantar flexors
Description: Deep Friction Massage was applied to both the gastrocnemius muscle and the Achilles tendon. Participants were positioned in a prone posture for both applications
Study: NCT06759077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA)
Description: adult patients with advanced CKD who will take SGL2I(DAPAGLIFLOZINE at a dose (10 mg/day) orally for 6months
Study: NCT06764342

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling combined with antimicrobial photodynamic therapy
Description: After full-mouth scaling procedures antimicrobial photodynamic therapy was carried out using a laser-activated disinfection device with a red laser emission (wavelength: 630 nm, irradiance: 2000-4000 mW/cm², spot size at the probe tip: 8 mm diameter) and high-viscosity methylene blue gel (0.1 mg/mL) which was applied at six spots on the tongue dorsum. Antimicrobial photodynamic therapy was also applied iIn sites with altered periodontal pocket depth (≥ 4mm). The dye remained in the pockets for 10 minutes to ensure full absorption and its excess was rinsed with sterile saline after laser exposure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: full-mouth scaling
Description: Full-mouth scaling within 24 hours, divided into two sessions of ultrasonic instrumentation followed by manual supra- and subgingival scaling and root planing. Tongue cleaning was performed with a tongue scraper.
Study: NCT06763549

Intervention type: DEVICE
Intervention: SUBPROTOCOL A
Description: A 30-minute COR ECG recording will be performed, including 15 minutes of continuous sitting data used for clinical indication analysis through CardioMIND software. Data collection can occur in-clinic, via PHS, or using a shipped device with telehealth support. Sleep, HRV, and AFIB risk analysis will not be included.

Intervention type: DEVICE
Intervention: SUBPROTOCOL B
Description: Subjects will undergo 24 hours of COR ECG recording, which must include at least one 15-minute unsupervised sitting session. Data analysis will include sleep patterns, HRV, and AFIB risk. ECG acquisition may take place in-clinic, via Patient Home Setup (PHS), or with a shipped device.

Intervention type: DEVICE
Intervention: SUBPROTOCOL C
Description: COR 1.0 ECG recordings will be conducted over 2 to 7 days, with at least one 15-minute unsupervised sitting session. At least 25% of randomly selected trial participants subjects will also wear a cleared wrist or finger device to track SpO2 during sleep. PI or Sub-Investigator will assign the number of wear days to the subject. The analysis will include sleep data, HRV, and AFIB risk assessment.

Intervention type: DEVICE
Intervention: SUBPROTOCOL D
Description: COR 2.0 (CORMDX) recordings will be conducted over 2 to 14 days, with at least one 15-minute unsupervised sitting session. At least 25% of randomly selected trial participants will also wear a cleared wrist or finger device to track SpO2 during sleep nights. PI or Sub-Investigator will assign the number of wear days to the subject. The analysis will include sleep data, HRV, and AFIB risk assessment.

Intervention type: DEVICE
Intervention: SUBPROTOCOL E
Description: Subjects will complete a 30-minute CORMDx (COR 2.0) ECG recording, with 15 minutes of continuous sitting data used for clinical indication analysis. Sleep, HRV, and AFIB risk analysis will not be performed.

Intervention type: DEVICE
Intervention: SUBPROTOCOL F
Description: A 30-minute COR 2.0 ECG recording will be completed, along with a 12-lead resting ECG using an FDA-cleared reference device. Sleep, HRV, and AFIB analysis will not be performed.

Intervention type: DEVICE
Intervention: SUBPROTOCOL G
Description: A 40-minute COR 2.0 recording will be conducted in two phases: 15 minutes of upright sitting and 15 minutes in a supine position. Hemodynamic monitoring, including blood pressure, cardiac output, and stroke volume variation, will be conducted using an FDA-cleared reference device. No sleep, HRV, or AFIB analysis will be performed.

Intervention type: DEVICE
Intervention: SUBPROTOCOL H
Description: Subjects will undergo a 40-minute COR 2.0 recording, followed by a 40-minute COR 1.0 recording. Hemodynamic monitoring using an FDA-cleared reference device will be performed during both sessions. The transition between devices must occur within 60 minutes if the same adhesive is reused. Sleep, HRV, and AFIB analysis will not be performed.
Study: NCT06763458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submaximal balloon angioplasty
Description: The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
Study: NCT06760325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tidal Model Intervention
Description: The model emphasizes long-term developmental care, extending support from hospital to home after discharge. This approach equips individuals with skills to understand and address challenges, emphasizing therapeutic interventions and sustained support through professionals or community groups. By focusing on the chaos and tide concepts of the Tidal Model, psychosocial interventions aim to enhance independence, manage symptoms, and improve quality of life.~In this arm, Tidal Model-based approaches will be applied during home visits to COPD patients. Within the scope of the intervention, psychosocial needs of patients will be assessed, individualized care plans will be created and symptom management and independence will be promoted by focusing on the chaos and tide concepts of the Tidal Model.
Study: NCT06762210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI Molar Mind
Description: a baseline oral health assessment using AI Molar Mind, which analyzes intraoral images and self-reported oral health data.
Study: NCT06764056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Participants receiving this intervention will be starting with a dose of semaglutide 0.25 mg. Physicians will follow Wegovy® Dosing Schedule guidelines, ending with a final dose of 2.4 mg at the fifth month. Type 2 diabetes participants wishing to stop at 1.0 mg will be allowed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Participants receiving this intervention will be starting with a dose of semaglutide 0.25 mg. Physicians will follow Wegovy® Dosing Schedule guidelines, ending with a final dose of 2.4 mg at the fifth month. Type 2 diabetes participants wishing to stop at 1.0 mg will be allowed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Participants receiving this intervention will be seeing a registered dietician at each visit. The individualized approach will be based on recent literature (mostly hypocaloric) by using different methods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Participants receiving this intervention will be seeing a registered dietician at each visit. The individualized approach will be based on recent literature (mostly hypocaloric) by using different methods.
Study: NCT06763614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dog assisted therapy - animal interventions
Description: Animal Assisted Therapy is when animals are used in goal directed treatment sessions. These goals are working emotionalaspects pf childres and adolescents with SAF
Study: NCT06764095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Undergo cytoreductive cystectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Therapy
Description: Undergo MDT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ureterectomy
Description: Undergo ureterectomy
Study: NCT06762938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: Apply ShotBlocker
Study: NCT06762769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Subcutaneous isatuximab will be delivered using an unlicensed medical device (On Body Delivery System)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibderomide
Description: Oral iberdomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dexamethasone
Study: NCT06763302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blinatumomab
Description: The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.
Study: NCT06763562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-first meal
Description: Rice eaten first (150 grams), followed by edamame (150 grams) and butter (10 grams)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-last meal
Description: Edamame (150 grams) and butter (10 grams) eaten first, followed by rice (150 grams)
Study: NCT06764680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluorouracil tepidopyrimidine
Description: 30mg/m2. P.O. bid. d1-d5 and d15-d19. q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluorouracil tepidopyrimidine
Description: 30mg/m2. P.O. bid. d1-d5 and d15-d19. q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg. ivgtt. d1 and d15. q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg. ivgtt. d1 and d15. q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindilizumab
Description: 200mg. ivgtt. d1. q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindilizumab
Description: 200mg. ivgtt. d1. q4w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: In terms of obstruction, bleeding, compression, or pain due to a tumor that requires local treatment. IMRT was delivered to the involved lesions.
Study: NCT06763965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioTTT001 injection
Description: BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 1.0×10\^10 viral particle (VP) ,5.0×10\^10 VP and 2.5×10\^11 VP based on the 3+3 dose escalation principle.